...

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

【24h】

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

机译：从第3阶段的疗效和安全性的疗效和安全性研究：Ibrutinib作为患者65岁及以上患者的一线治疗选择，慢性淋巴细胞白血病/小淋巴细胞白血病

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共6页
作者
Barr Paul; Robak Tadeusz; Owen Carolyn J.; Tedeschi Alessandra; Bairey Osnat; Bartlett Nancy L.; Burger Jan; Hillmen Peter; Coutre Steven; Devereux Stephen; Grosicki Sebastian; McCarthy Helen; Li Jianyong; Simpson David; Offner Fritz; Moreno Carol; Zhou Cathy; Styles Lori; James Danelle F.; Kipps Thomas J.; Ghia Paolo;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia [J] . Barr Paul, Robak Tadeusz, Owen Carolyn J., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：从第3阶段的疗效和安全性的疗效和安全性研究：Ibrutinib作为患者65岁及以上患者的一线治疗选择，慢性淋巴细胞白血病/小淋巴细胞白血病
2. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 [J] . Paul M. Barr, Tadeusz Robak, Carolyn Owen, Haematologica . 2018,第9期

机译：一线依鲁替尼治疗老年慢性淋巴细胞白血病的持续疗效和详细的临床随访：RESONATE-2延长的3期临床结果
3. A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia 65 Years Old or with Coexisting Conditions [J] . Lujan Juliana Velez, Choi Michael Y., Jacobs Chaja, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：IBrutinib的IB / II研究与Obinutuzumab-Gazyva组合作为慢性淋巴细胞白血病患者的一线治疗。 65岁或与共存条件
4. A Multiple Treatments Meta-Analysis of a Response to the First-Line Treatment of the Chronic Lymphocytic Leukemia [C] . Maria Molik, Piotr Ladyzynski, Piotr Foltynski International Federation for Medical and Biological Engineering European Conference . 2015

机译：多种治疗Meta分析对慢性淋巴细胞白血病的一线治疗的反应
5. Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315. [D] . Liu, Ta-Ming. 2014

机译：激酶靶向疗法在慢性淋巴细胞性白血病中：获得性依鲁替尼耐药性的机制和OSU-T315的临床前开发。
6. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 [O] . Paul M. Barr, Tadeusz Robak, Carolyn Owen, 2018

机译：一线依鲁替尼治疗老年慢性淋巴细胞白血病的持续疗效和详细的临床随访：RESONATE-2延长的3期临床结果
7. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 [O] . Paul M. Barr, Tadeusz Robak, Carolyn Owen, 2018

机译：在慢性淋巴细胞白血病患者中持续的初级伊布勒替尼治疗的持续疗效和详细的临床后续随访：共激发-2的延长阶段3结果

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号